BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24589490)

  • 1. Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection.
    Nantasenamat C; Monnor T; Worachartcheewan A; Mandi P; Isarankura-Na-Ayudhya C; Prachayasittikul V
    Eur J Med Chem; 2014 Apr; 76():352-9. PubMed ID: 24589490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinoxalinones Based Aldose Reductase Inhibitors: 2D and 3D-QSAR Analysis.
    Masand VH; Elsayed NN; Thakur SD; Gawhale N; Rathore MM
    Mol Inform; 2019 Aug; 38(8-9):e1800149. PubMed ID: 31131980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure and aldose reductase inhibitory activity relationship of 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone derivatives.
    Ko K; Won Y
    Bioorg Med Chem; 2005 Mar; 13(5):1445-52. PubMed ID: 15698760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of QSAR modelling techniques and their combination to rationalize the physicochemical characters of nitrophenyl derivatives towards aldose reductase inhibition.
    Soni LK; Gupta AK; Kaskhedikar SG
    J Enzyme Inhib Med Chem; 2009 Aug; 24(4):1002-7. PubMed ID: 19514863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative structure-activity relationship study of aromatic inhibitors against rat lens aldose reductase activity using variable selections.
    Jung M; Lee Y; Shim M; Lim E; Lee EJ; Lee HC
    Med Chem; 2013 May; 9(3):410-9. PubMed ID: 22931492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors.
    Hu L; Chen G; Chau RM
    J Mol Graph Model; 2006 Jan; 24(4):244-53. PubMed ID: 16226911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high dimensional QSAR study on the aldose reductase inhibitory activity of some flavones: topological descriptors in modeling the activity.
    Prabhakar YS; Gupta MK; Roy N; Venkateswarlu Y
    J Chem Inf Model; 2006; 46(1):86-92. PubMed ID: 16426043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative structure-activity relationship of spirosuccinimide type aldose reductase inhibitors diminishing sorbitol accumulation in vivo.
    Ko K; Won H; Won Y
    Bioorg Med Chem; 2006 May; 14(9):3090-7. PubMed ID: 16412651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors.
    Sambasivarao SV; Soni LK; Gupta AK; Hanumantharao P; Kaskhedikar SG
    Bioorg Med Chem Lett; 2006 Feb; 16(3):512-20. PubMed ID: 16297625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR prediction of inhibition of aldose reductase for flavonoids.
    Mercader AG; Duchowicz PR; Fernández FM; Castro EA; Bennardi DO; Autino JC; Romanelli GP
    Bioorg Med Chem; 2008 Aug; 16(15):7470-6. PubMed ID: 18585047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR (CoMFA and CoMSIA) and pharmacophore (GALAHAD) studies on the differential inhibition of aldose reductase by flavonoid compounds.
    Caballero J
    J Mol Graph Model; 2010 Nov; 29(3):363-71. PubMed ID: 20863730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR modeling of aromatase inhibitory activity of 1-substituted 1,2,3-triazole analogs of letrozole.
    Nantasenamat C; Worachartcheewan A; Prachayasittikul S; Isarankura-Na-Ayudhya C; Prachayasittikul V
    Eur J Med Chem; 2013 Nov; 69():99-114. PubMed ID: 24012714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose reductase inhibitors for diabetic complications: Receptor induced atom-based 3D-QSAR analysis, synthesis and biological evaluation.
    Vyas B; Singh M; Kaur M; Bahia MS; Jaggi AS; Silakari O; Singh B
    J Mol Graph Model; 2015 Jun; 59():59-71. PubMed ID: 25911954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of bioactivity of ACAT2 inhibitors by multilinear regression analysis and support vector machine.
    Zhong M; Xuan S; Wang L; Hou X; Wang M; Yan A; Dai B
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3788-92. PubMed ID: 23711921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative structure-activity relationship to predict differential inhibition of aldose reductase by flavonoid compounds.
    Fernández M; Caballero J; Helguera AM; Castro EA; González MP
    Bioorg Med Chem; 2005 May; 13(9):3269-77. PubMed ID: 15809162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus.
    Patra JC; Singh O
    J Comput Chem; 2009 Nov; 30(15):2494-508. PubMed ID: 19373836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel synthesis of nitro-quinoxalinone derivatives as aldose reductase inhibitors.
    Hussain S; Parveen S; Qin X; Hao X; Zhang S; Chen X; Zhu C; Ma B
    Bioorg Med Chem Lett; 2014 May; 24(9):2086-9. PubMed ID: 24726808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
    Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
    J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of ganoderma acids from Ganoderma lucidum as aldose reductase inhibitors.
    Fatmawati S; Shimizu K; Kondo R
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7295-7. PubMed ID: 22047696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted derivatives of indole acetic acid as aldose reductase inhibitors with antioxidant activity: structure-activity relationship.
    Juskova M; Majekova M; Demopoulos V; Stefek M
    Gen Physiol Biophys; 2011 Dec; 30(4):342-9. PubMed ID: 22131315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.